View ValuationBICO Group 将来の成長Future 基準チェック /16BICO Group利益と収益がそれぞれ年間97.6%と7.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-2.6% 97.7%なると予測されています。主要情報97.6%収益成長率97.67%EPS成長率Life Sciences 収益成長20.1%収益成長率7.7%将来の株主資本利益率-2.64%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Breakeven Date Change • Dec 30Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Member of Scientific Advisory Board Ali Khademhosseini is the most experienced director on the board, commencing their role in 2017. Independent Director Chris Wildmoser was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.Breakeven Date Change • Dec 30Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance.お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.New Risk • Jun 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year).Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.Reported Earnings • May 07First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Feb 21Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.Reported Earnings • Nov 17Third quarter 2023 earnings released: kr1.00 loss per share (vs kr1.04 profit in 3Q 2022)Third quarter 2023 results: kr1.00 loss per share (down from kr1.04 profit in 3Q 2022). Revenue: kr626.2m (flat on 3Q 2022). Net loss: kr70.6m (down 206% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Nov 17Group Chief Financial Officer recently bought €75k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly €4.30 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.Reported Earnings • May 09First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024Buying Opportunity • Feb 22Now 39% undervalued after recent price dropOver the last 90 days, the stock is down 9.7%. The fair value is estimated to be €9.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has declined by 70%. Revenue is forecast to grow by 1.1% in a year. Earnings is forecast to grow by 92% in the next year.Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold €747k worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly €9.33 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by €654k.お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 13% growth forecast for the Life Sciences industry in Germany.Breakeven Date Change • Jul 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.お知らせ • May 18BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2023Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Mar 04Co-Founder recently bought €94k worth of stockOn the 2nd of March, Erik Gatenholm bought around 6k shares on-market at roughly €15.89 per share. In the last 3 months, they made an even bigger purchase worth €1.9m. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr3.97 loss per share (down from kr0.82 loss in FY 2020). Revenue: kr1.43b (up 283% from FY 2020). Net loss: kr227.6m (loss widened kr191.5m from FY 2020). Post-clinical trial products Launched (during full year): 3 Revenue exceeded analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 66%, compared to a 25% growth forecast for the pharmaceuticals industry in Germany.Recent Insider Transactions • Dec 18Co-Founder recently bought €1.9m worth of stockOn the 16th of December, Erik Gatenholm bought around 74k shares on-market at roughly €26.32 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr347.3m (up 457% from 3Q 2020). Net loss: kr104.2m (loss widened kr90.0m from 3Q 2020).Recent Insider Transactions • Sep 01Insider recently sold €1.1m worth of stockOn the 23rd of August, Jonas Schondube sold around 20k shares on-market at roughly €53.24 per share. In the last 3 months, there was an even bigger sale from another insider worth €17m. Insiders have been net sellers, collectively disposing of €50m more than they bought in the last 12 months.Recent Insider Transactions • Aug 25CEO & Director recently sold €17m worth of stockOn the 18th of August, Erik Gatenholm sold around 280k shares on-market at roughly €59.24 per share. This was the largest sale by an insider in the last 3 months. This was Erik's only on-market trade for the last 12 months.Reported Earnings • Aug 21Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr328.4m (up kr275.8m from 2Q 2020). Net loss: kr50.3m (loss widened 99% from 2Q 2020).Reported Earnings • May 13First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved revenues, although losses increased and control over costs was weaker. First quarter 2021 results: Revenue: kr153.5m (up 171% from 1Q 2020). Net loss: kr47.5m (loss widened 176% from 1Q 2020).Is New 90 Day High Low • Feb 12New 90-day high: €28.85The company is up 64% from its price of €17.62 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 27New 90-day high: €28.35The company is up 70% from its price of €16.70 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 7.0% over the same period.お知らせ • Dec 19Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of DirectorsCellink AB (publ) announced that at the extraordinary general meeting in CELLINK AB (publ), held on December 17, 2020 approved to elect Aristotelis Nastos as a new member of the board of directors of Cellink.Is New 90 Day High Low • Dec 18New 90-day high: €20.75The company is up 24% from its price of €16.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.お知らせ • Dec 05CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting CommunityCELLINK and Atelerix partnership to bring to market Atelerix's portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for damaging biological material. Therefore, the global bioprinting community will greatly benefit from Atelerix products that allow for room-temperature storage and shipping of sensitive primary cells, iPSC-derived cells, multicellular models and especially cell-laden bioprinted constructs, such as those manufactured with CELLINK's range of innovative 3D bioprinters. Atelerix's range of innovative products, including BeadReady™ (used for cells in suspension), WellReady™ (used for plated cells and cell-laden bioprinted constructs) and TissueReady™ (used for tissue samples and larger cell-laden bioprinted constructs), will be available for purchase from CELLINK, so that the research community may procure all their bioprinting requirements in one place.お知らせ • Nov 10CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle ProjectThe TRIANKLE consortium - made up of 12 European organisations, will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joints. This ambitious research project in regenerative medicine has an overall budget of €5.9 Million and will be developed over 4 years, starting January 2021. CELLINK's portion of the grant is. €622,000 of which EU accounts for 100 percent of the costs. The consortium aims to create innovative personalised collagen- and gelatine-based implants manufactured with 3D technology for patients with tendinopathies such as Achilles tendon partial ruptures and cartilage injuries. TRIANKLE consortium consists of a team of 12 organizations covering the complete spectrum from advanced research to the market. Its main strength relies on the combination of highly skilled partners with proven track records in biomaterials for regenerative applications and 3D bioprinting technology. Partners are also devoted to social engagement and dissemination of results to healthcare professionals and, ultimately, potential patients. A total of 12 organizations from 5 different countries (Germany, Spain, Sweden, the Netherlands, and the United Kingdom) make up the TRIANKLE consortium. The partnership includes one industry partner (Naturin Viscofan GmbH), three SMEs (CELLINK AB, Cambridge Nanomaterials Technology, and Gradocell SL), two research centres (Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. and Acondicionamiento Tarrasense Associacion), three universities (University of Stuttgart, Universidad del País Vasco and Eindhoven University of Technology), two non-profit organizations (Futbol Club Barcelona Asociacion FCB and Osteoarthritis Foundation International OAFI) and one healthcare institution (Fundacio Clinic per a la Recerca Biomedica). The TRIANKLE project coordinator is Naturin Viscofan GmbH.Reported Earnings • Oct 22Full year earnings released - €1.47 loss per shareOver the last 12 months the company has reported total losses of kr61.9m, with earnings decreasing by kr62.4m from the prior year. Total revenue was kr235.7m over the last 12 months, up 75% from the prior year.お知らせ • Oct 20+ 1 more updateCellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020Cellink AB (publ) announced that they will report second half, 2020 results on Oct 22, 2020お知らせ • Oct 03Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business UnitArtur Aira, is leaving the CELLINK Board of Directors for an operational role as Business Area Manager for the bioprinting business unit.業績と収益の成長予測DB:49Z - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,839-4985126312/31/20271,689-112-1144312/31/20261,566-207-97-5633/31/20261,492-1,4771539N/A12/31/20251,497-1,5804368N/A9/30/20251,561-1,270159199N/A6/30/20251,543-424216275N/A3/31/20251,642-323176252N/A12/31/20241,727-10773158N/A9/30/20241,609-80348139N/A6/30/20241,828-583-3598N/A3/31/20241,941-729-98101N/A12/31/20232,010-788-113178N/A9/30/20232,213-497-435-53N/A6/30/20232,256-390-527-72N/A3/31/20232,297-117-643-140N/A12/31/20222,327-85-799-269N/A9/30/20222,27841-817-313N/A6/30/20221,995-130-872-457N/A3/31/20221,743-224-816-462N/A12/31/20211,378-228-676-409N/A9/30/2021993-188-529-321N/A6/30/2021744-96-328-150N/A3/31/2021460-50-156-34N/A12/31/2020369-36-160-59N/A8/31/2020236-62-154-72N/A5/31/2020213-49-146-70N/A2/29/2020197-24N/A-53N/A11/30/2019173-5N/A-31N/A8/31/20191351N/A-16N/A5/31/20191183N/A-16N/A2/28/2019974N/A-2N/A11/30/2018762N/A-12N/A8/31/2018611N/A-12N/A5/31/2018451N/A-6N/A2/28/201834-2N/A-7N/A11/30/201727-2N/A-8N/A8/31/201720-1N/A-1N/A8/31/20166-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 49Zの収益 ( 7.7% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: 49Zの収益 ( 7.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 49Z 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 19:29終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BICO Group AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kristofer Liljeberg-SvenssonDNB CarnegieLudvig LundgrenNordea MarketsFilip EinarssonRedeye
Breakeven Date Change • Dec 30Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.
Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.
Board Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (5 non-independent directors). Member of Scientific Advisory Board Ali Khademhosseini is the most experienced director on the board, commencing their role in 2017. Independent Director Chris Wildmoser was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.
お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.
お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.
お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.
お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.
お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.
Breakeven Date Change • Dec 30Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.
Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025
お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.
Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.
New Risk • Jun 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year).
Breakeven Date Change • Jun 10No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.
お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.
Reported Earnings • May 07First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.
お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.
お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025
お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Feb 21Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.
Reported Earnings • Nov 17Third quarter 2023 earnings released: kr1.00 loss per share (vs kr1.04 profit in 3Q 2022)Third quarter 2023 results: kr1.00 loss per share (down from kr1.04 profit in 3Q 2022). Revenue: kr626.2m (flat on 3Q 2022). Net loss: kr70.6m (down 206% from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Nov 17Group Chief Financial Officer recently bought €75k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly €4.30 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.
お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024
Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.
お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.
Reported Earnings • May 09First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024
Buying Opportunity • Feb 22Now 39% undervalued after recent price dropOver the last 90 days, the stock is down 9.7%. The fair value is estimated to be €9.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 82% over the last 3 years. Earnings per share has declined by 70%. Revenue is forecast to grow by 1.1% in a year. Earnings is forecast to grow by 92% in the next year.
Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold €747k worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly €9.33 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by €654k.
お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.
お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.
Board Change • Nov 16High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023
Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 13% growth forecast for the Life Sciences industry in Germany.
Breakeven Date Change • Jul 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.
お知らせ • May 18BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2023
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Mar 04Co-Founder recently bought €94k worth of stockOn the 2nd of March, Erik Gatenholm bought around 6k shares on-market at roughly €15.89 per share. In the last 3 months, they made an even bigger purchase worth €1.9m. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.
Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr3.97 loss per share (down from kr0.82 loss in FY 2020). Revenue: kr1.43b (up 283% from FY 2020). Net loss: kr227.6m (loss widened kr191.5m from FY 2020). Post-clinical trial products Launched (during full year): 3 Revenue exceeded analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 66%, compared to a 25% growth forecast for the pharmaceuticals industry in Germany.
Recent Insider Transactions • Dec 18Co-Founder recently bought €1.9m worth of stockOn the 16th of December, Erik Gatenholm bought around 74k shares on-market at roughly €26.32 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.
Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr347.3m (up 457% from 3Q 2020). Net loss: kr104.2m (loss widened kr90.0m from 3Q 2020).
Recent Insider Transactions • Sep 01Insider recently sold €1.1m worth of stockOn the 23rd of August, Jonas Schondube sold around 20k shares on-market at roughly €53.24 per share. In the last 3 months, there was an even bigger sale from another insider worth €17m. Insiders have been net sellers, collectively disposing of €50m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 25CEO & Director recently sold €17m worth of stockOn the 18th of August, Erik Gatenholm sold around 280k shares on-market at roughly €59.24 per share. This was the largest sale by an insider in the last 3 months. This was Erik's only on-market trade for the last 12 months.
Reported Earnings • Aug 21Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr328.4m (up kr275.8m from 2Q 2020). Net loss: kr50.3m (loss widened 99% from 2Q 2020).
Reported Earnings • May 13First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved revenues, although losses increased and control over costs was weaker. First quarter 2021 results: Revenue: kr153.5m (up 171% from 1Q 2020). Net loss: kr47.5m (loss widened 176% from 1Q 2020).
Is New 90 Day High Low • Feb 12New 90-day high: €28.85The company is up 64% from its price of €17.62 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 27New 90-day high: €28.35The company is up 70% from its price of €16.70 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 7.0% over the same period.
お知らせ • Dec 19Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of DirectorsCellink AB (publ) announced that at the extraordinary general meeting in CELLINK AB (publ), held on December 17, 2020 approved to elect Aristotelis Nastos as a new member of the board of directors of Cellink.
Is New 90 Day High Low • Dec 18New 90-day high: €20.75The company is up 24% from its price of €16.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.
お知らせ • Dec 05CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting CommunityCELLINK and Atelerix partnership to bring to market Atelerix's portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for damaging biological material. Therefore, the global bioprinting community will greatly benefit from Atelerix products that allow for room-temperature storage and shipping of sensitive primary cells, iPSC-derived cells, multicellular models and especially cell-laden bioprinted constructs, such as those manufactured with CELLINK's range of innovative 3D bioprinters. Atelerix's range of innovative products, including BeadReady™ (used for cells in suspension), WellReady™ (used for plated cells and cell-laden bioprinted constructs) and TissueReady™ (used for tissue samples and larger cell-laden bioprinted constructs), will be available for purchase from CELLINK, so that the research community may procure all their bioprinting requirements in one place.
お知らせ • Nov 10CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle ProjectThe TRIANKLE consortium - made up of 12 European organisations, will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joints. This ambitious research project in regenerative medicine has an overall budget of €5.9 Million and will be developed over 4 years, starting January 2021. CELLINK's portion of the grant is. €622,000 of which EU accounts for 100 percent of the costs. The consortium aims to create innovative personalised collagen- and gelatine-based implants manufactured with 3D technology for patients with tendinopathies such as Achilles tendon partial ruptures and cartilage injuries. TRIANKLE consortium consists of a team of 12 organizations covering the complete spectrum from advanced research to the market. Its main strength relies on the combination of highly skilled partners with proven track records in biomaterials for regenerative applications and 3D bioprinting technology. Partners are also devoted to social engagement and dissemination of results to healthcare professionals and, ultimately, potential patients. A total of 12 organizations from 5 different countries (Germany, Spain, Sweden, the Netherlands, and the United Kingdom) make up the TRIANKLE consortium. The partnership includes one industry partner (Naturin Viscofan GmbH), three SMEs (CELLINK AB, Cambridge Nanomaterials Technology, and Gradocell SL), two research centres (Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. and Acondicionamiento Tarrasense Associacion), three universities (University of Stuttgart, Universidad del País Vasco and Eindhoven University of Technology), two non-profit organizations (Futbol Club Barcelona Asociacion FCB and Osteoarthritis Foundation International OAFI) and one healthcare institution (Fundacio Clinic per a la Recerca Biomedica). The TRIANKLE project coordinator is Naturin Viscofan GmbH.
Reported Earnings • Oct 22Full year earnings released - €1.47 loss per shareOver the last 12 months the company has reported total losses of kr61.9m, with earnings decreasing by kr62.4m from the prior year. Total revenue was kr235.7m over the last 12 months, up 75% from the prior year.
お知らせ • Oct 20+ 1 more updateCellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020Cellink AB (publ) announced that they will report second half, 2020 results on Oct 22, 2020
お知らせ • Oct 03Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business UnitArtur Aira, is leaving the CELLINK Board of Directors for an operational role as Business Area Manager for the bioprinting business unit.